Spots Global Cancer Trial Database for advanced solid tumors cancer
Every month we try and update this database with for advanced solid tumors cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| First In Human Study With ABBV-CLS-579 When Given Alone and In Combination In Participants With Locally Advanced Or Metastatic Tumors | NCT04417465 | Advanced Solid ... | ABBV-CLS-579 PD-1 inhibitor VEGFR TKI | 18 Years - | Calico Life Sciences LLC | |
| A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors | NCT02099058 | Advanced Solid ... | Osimertinib Nivolumab Telisotuzumab v... Telisotuzumab v... Erlotinib | 18 Years - | AbbVie | |
| A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid Tumors | NCT02988960 | Advanced Solid ... | ABBV-927 ABBV-927 ABBV-181 | 18 Years - | AbbVie | |
| A Study to Determine Safety, Tolerability, Pharmacokinetics, and Recommended Phase 2 Dose (RP2D) of Intravenous ABBV-184 in Adult Participants With Previously Treated Cancers | NCT04272203 | Acute Myeloid L... Non Small Cell ... Cancer | ABBV-184 | 18 Years - | AbbVie | |
| Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors | NCT04721015 | Advanced Solid ... Non Small Cell ... | ABBV-637 Docetaxel Osimertinib | 18 Years - | AbbVie | |
| A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma | NCT05929235 | Advanced Solid ... Advanced Urothe... Oral Drug Admin... Open Label | FX-909 | 18 Years - | Flare Therapeutics Inc. | |
| A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma | NCT05929235 | Advanced Solid ... Advanced Urothe... Oral Drug Admin... Open Label | FX-909 | 18 Years - | Flare Therapeutics Inc. | |
| A Study to Evaluate the Safety and Pharmacokinetics ABBV-399 in Japanese Participants With Solid Tumors | NCT03311477 | Advanced Solid ... | ABBV-399 | 20 Years - | AbbVie | |
| A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors | NCT02099058 | Advanced Solid ... | Osimertinib Nivolumab Telisotuzumab v... Telisotuzumab v... Erlotinib | 18 Years - | AbbVie | |
| A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors | NCT06270706 | Metastatic Soli... | PLN-101095 Pembrolizumab | 18 Years - | Pliant Therapeutics, Inc. | |
| A Study of ABBV-428, an Immunotherapy, in Subjects With Advanced Solid Tumors | NCT02955251 | Advanced Solid ... | ABBV-428 Nivolumab | 18 Years - 99 Years | AbbVie | |
| A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors | NCT03071757 | Advanced Solid ... | ABBV-368 ABBV-181 | 18 Years - | AbbVie | |
| Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors | NCT03821935 | Advanced Solid ... | Livmoniplimab Budigalimab | 18 Years - | AbbVie | |
| A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors | NCT03071757 | Advanced Solid ... | ABBV-368 ABBV-181 | 18 Years - | AbbVie | |
| A Study Evaluating the Safety, Pharmacokinetics and Anti-Tumor Activity of ABBV-176 in Subjects With Advanced Solid Tumors Likely to Express Prolactin Receptor (PRLR) | NCT03145909 | Advanced Solid ... | ABBV-176 | 18 Years - | AbbVie | |
| A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | NCT04196283 | Advanced Solid ... | ABBV-368 Tilsotolimod Nab-paclitaxel ABBV-181 | 18 Years - | AbbVie | |
| Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors | NCT03821935 | Advanced Solid ... | Livmoniplimab Budigalimab | 18 Years - | AbbVie |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
